This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation


Lott, Ira T., Doran, Eric, Nguyen, Vinh Q., Tournay, Anne, Head, Elizabeth, Gillen, Daniel L.


American Journal Of Medical Genetics. Part A, Volume: 155A, No.: 8, Pages.: 1939-1948

Year of Publication



Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. There is a paucity of treatment trials for dementia in Down syndrome in comparison to Alzheimer disease in the general (non-Down syndrome) population. This 2-year randomized, double-blind, placebo-controlled trial assessed whether daily oral antioxidant supplementation (900 IU of alpha-tocopherol, 200 mg of ascorbic acid and 600 mg of alpha-lipoic acid) was effective, safe and tolerable for 53 individuals with Down syndrome and dementia. The outcome measures comprised a battery of neuropsychological assessments administered at baseline and every 6 months. Compared to the placebo group, those individuals receiving the antioxidant supplement showed neither an improvement in cognitive functioning nor a stabilization of cognitive decline. Mean plasma levels of alpha-tocopherol increased ~2-fold in the treatment group and were consistently higher than the placebo group over the treatment period. Pill counts indicated good compliance with the regimen. No serious adverse events attributed to the treatment were noted. We conclude that antioxidant supplementation is safe, though ineffective as a treatment for dementia in individuals with Down syndrome and Alzheimer type dementia. Our findings are similar to studies of antioxidant supplementation in Alzheimer disease in the general population. The feasibility of carrying out a clinical trial for dementia in Down syndrome is demonstrated.; Copyright © 2011 Wiley-Liss, Inc.

Bibtex Citation

@article{Lott_2011, doi = {10.1002/ajmg.a.34114}, url = {}, year = 2011, month = {jul}, publisher = {Wiley-Blackwell}, volume = {155}, number = {8}, pages = {1939--1948}, author = {Ira T. Lott and Eric Doran and Vinh Q. Nguyen and Anne Tournay and Elizabeth Head and Daniel L. Gillen}, title = {Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation}, journal = {Am. J. Med. Genet.} }


adverse, alzheimer disease, antioxidants, ascorbic acid, complications, down syndrome, drug combinations, drug therapy, events, feasibility studies, female, humans, male, middle aged, pilot projects, therapeutic use, thioctic acid, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease, Dementia (general / unspecified)

Types of Study

Randomised Controlled Trial

Type of Outcomes

Behaviour, Cognition, Other

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Herbal remedies, vitamins, dietary supplements